EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preclinical Evaluation of the Oral Toxicity, Genotoxicity, and Safety Pharmacology of LPM4870108 , a Novel Potent Tropomyosin Receptor Kinase Inhibitor

Xiaochen Zhang iD, Baiyang Yuan, Chunmei Li, Hongbo Wang iD, Shujuan Wei, Jingwei Tian, Sijin Duan

Pharmacology Research & Perspectives · 2025-08 · 13 (4)

DOI: 10.1002/prp2.70153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 11.08.2025. Verfasst von Xiaochen Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced …. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Receptor, trkA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Initial Scientific Research Fund of Yantai University, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tropomyosin receptor kinase (Trk) inhibitors are an essential class of anticancer drugs treating NTRK gene fusions‐positive cancer. However, the potential for the emergence of on‐target resistance suggests newer Trk inhibitors with low drug resistance risk are needed. LPM4870108 is a novel Trk inhibitor with robust anticancer efficacy in preclinical studies. To support future clinical development, this study systematically evaluated the acute and subacute (4‐week) toxicity, toxicokinetic, genotoxic, and safety pharmacology of LPM4870108. The acute toxicity study revealed the maximum tolerated dose of LPM4870108 was 300 mg/kg, whereas subacute studies determined its STD 10 in rats was 10 mg/kg/day. The toxicological effects of LPM4870108 were consistent with its pharmacodynamic efficacies as a Trk inhibitor, including corneal inflammation, splenic lymphocytopenia, hepatocyte vacuolar degeneration, scab formation, and increased food consumption and body weight. These changes were partially or fully recovered after 4 weeks of recovery. In rats treated with 10 or 20 mg/kg/day, 2/30, or 6/30 rats died or were moribund, and the primary organs affected by treatment‐related toxicity included the eyes, liver, and skin. Rat toxicokinetic findings were consistent with a dose‐dependent effect of LPM4870108. There was no evidence of LPM4870108‐related genotoxicity, nor did it affect respiratory function or neurobehavioral activity in rats or blood pressure or electrocardiogram results in rhesus monkeys. The IC 50 of LPM4870108 for hERG current inhibition was 18.2 μM. Together, these results demonstrate that LPM4870108 exhibits a satisfactory safety profile which is appropriate for further clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsReceptor, trkAAnimalsFemaleMaleRatsDrug Evaluation, PreclinicalMutagenicity TestsRandom AllocationRats, Sprague-DawleyToxicity Tests, SubacuteMaximum Tolerated DoseMacaca mulattaHeterocyclic Compounds, 4 or More Rings

Stichwörter der Autor:innen

LPM4870108genotoxicitysafety pharmacologytoxicity studytoxicokinetic

Substanzen

LPM4870108Protein Kinase InhibitorsReceptor, trkAHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Ya…
  • State Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co., Ltd., Yantai, Shandong, People's Republic of China.

ORCID-Profile: Xiaochen Zhang, Hongbo Wang

Förderung

  • Initial Scientific Research Fund of Yantai University
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Zhang, X., Yuan, B., Li, C., Wang, H., Wei, S., Tian, J., & Duan, S. (2025). Preclinical Evaluation of the Oral Toxicity, Genotoxicity, and Safety Pharmacology of LPM4870108 , a Novel Potent Tropomyosin Receptor Kinase Inhibitor. Pharmacology Research & Perspectives, 13(4). https://doi.org/10.1002/prp2.70153

Vancouver

Zhang X, Yuan B, Li C, Wang H, Wei S, Tian J, et al. Preclinical Evaluation of the Oral Toxicity, Genotoxicity, and Safety Pharmacology of LPM4870108 , a Novel Potent Tropomyosin Receptor Kinase Inhibitor. Pharmacology Research & Perspectives. 2025;13(4). doi:10.1002/prp2.70153

BibTeX
@article{Zhang2025,
  author = {Zhang, Xiaochen and Yuan, Baiyang and Li, Chunmei and Wang, Hongbo and Wei, Shujuan and Tian, Jingwei and Duan, Sijin},
  title = {Preclinical Evaluation of the Oral Toxicity, Genotoxicity, and Safety Pharmacology of LPM4870108 , a Novel Potent Tropomyosin Receptor Kinase Inhibitor},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  volume = {13},
  number = {4},
  doi = {10.1002/prp2.70153}
}
Kostenlos starten →